The headline number is real: colorectal cancer diagnoses in under-50s in England went from roughly 1 in 26,000 to 1 in 12,000 between 2001 and 2023. The World Cancer Research Fund found new case rates rising across seven cancers in England alone, with similar patterns in the US and the Netherlands. A 50-country study published in 2025 found early-onset colorectal cancer climbing in 27 regions, with Chile posting nearly 4% annual growth. At one São Paulo hospital, cases in under-50s rose five-fold. But the picture is more complicated than the numbers suggest. Amy Berrington de Gonzalez, professor of clinical epidemiology at the Institute of Cancer Research in London, points out that cancer in young people remains uncommon in absolute terms — 'three times a small number is still a small number.' A US study on pancreatic cancer in young adults found the rise was almost entirely early-stage tumors, with death rates unchanged, suggesting better detection rather than more disease. Colorectal cancer, however, shows a different signature: US data reveals increases in advanced-stage diagnoses, which cannot be explained away by screening alone. The obesity link is now well-established. The WHO's International Agency for Research on Cancer identifies obesity as a cause of at least 13 cancers. A 2021 review found young adults with obesity were nearly twice as likely to develop colorectal cancer before 50. Obesity rates have doubled among adults since the 1990s and quadrupled among adolescents — a timeline that tracks the cancer rise closely. Diet and lifestyle round out the usual suspects: processed meat is classified as carcinogenic, alcohol is a risk factor, and fiber intake lowers risk. Ultra-processed foods and microplastics generate headlines but not yet conclusive evidence. Marc Gunter of Imperial College London warns against the hype: more research is needed. What he does consider settled is the role of sedentary, convenience-food societies — and that Latin America is now following the same trajectory as wealthier nations. The structural problem is data infrastructure. Brazil and Mexico lack comprehensive cancer registries, making it impossible to distinguish a true surge from a hospital-level artifact. The São Paulo hospital's five-fold increase may reflect one facility treating more patients, not a national epidemic. Berrington de Gonzalez's call for better registration systems is not academic — without them, the signal stays buried in noise. Berrington de Gonzalez's 42-country study found six cancers — thyroid, breast, colorectal, kidney, uterine, and leukemia — rising in 20-to-49-year-olds across most countries. Colorectal cancer stood out uniquely: in about a third of countries, it rose faster in younger adults than in older ones, even as rates in the over-50s declined. This divergence suggests something specific is happening to younger cohorts, not just a population-wide trend. Gunter places responsibility where it belongs: not on individuals making bad choices, but on societies built around desk jobs and convenience food. Lasting change, he says, requires public health policy. For anyone under 50 reading this, the practical advice is unglamorous — more walking, more vegetables, less processed meat — and the reassurance is genuine: early-onset cancer, while rising, remains rare.
